Semarion raises £2.14 million GBP seed funding

Semarion’s cell assaying platform turns adherent cells into liquid reagents to enable novel drug screening methodologies

24-Feb-2022 - Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, announced that it has closed a £2.14 million GBP seed funding round. The investment round was led by Parkwalk Advisors, ...

ibidi Awarded with the Export Award Bavaria: Special Edition 2021

02-Dec-2021 - For its excellent crisis strategy during the pandemic, ibidi GmbH has been awarded the Export Award Bavaria 2021: Special Edition 2021, in the category, "Successful Order Processing in Corona Times." The award, which has been presented since 2007 to small- and medium-sized companies that work ...

Max Planck Innovation awards license for actin marker LifeAct

Max Planck Innovation and ibidi sign license agreement for cytoskeleton research

28-Jul-2010 - Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, has awarded an exclusive license for LifeAct to ibidi GmbH, a provider of cell analysis products, located in Martinsried near Munich. The novel peptide allows for actin, an important protein, to be made ...

InteRNA Technologies and Dana-Farber Cancer Institute to collaborate on the role of microRNAs in cancer pathways

03-Nov-2009 - InteRNA Technologies B.V. and the Dana-Farber Cancer Institute have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for cancer. Under the research collaboration with Associate Professor William C. Hahn, MD, PhD (Department of Medical Oncology), InteRNA’s ...

InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer

24-Apr-2009 - InteRNA Technologies B.V. and Radboud University Nijmegen Medical Centre have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for prostate cancer. Under the research collaboration with professor Jack Schalken (Laboratory of Experimental Urology), InteRNA’s unique ...

ibidi establishes partnership with Seahorse Bioscience

05-Feb-2009 - ibidi GmbH announced a partnership with Seahorse Bioscience, Inc. of Billerica; Main, USA. Under the terms of the agreement ibidi will exclusively distribute the products of Seahorse Bioscience in Germany and Austria. With this partnership ibidi further strengthens its position as a service ...

Roche and ACEA enter exclusive world-wide agreement

Roche Applied Science acquires innovative key technology for cell-analysis

19-Nov-2007 - Roche and ACEA Biosciences Inc. announced that they have entered into an exclusive agreement for the development, supply and distribution for ACEA Bioscience's real-time cell assay technology. Under the terms of the agreement, RAS will exclusively market systems for real-time cell analysis, based ...

amaxa to Co-ordinate Collaboration to Develop High-throughput Devices for Primary Cell Transfection

04-Jul-2007 - amaxa AG has announced that it will co-ordinate a European collaboration of eight partners to develop devices for ultra high-throughput delivery and screening of primary cells, for use in the study of immunological, neuronal and liver disorders, for example. The collaboration has been granted ...

ITI Life Sciences signs commercialisation licence agreements with Edinburgh Instruments and Almac Sciences (Scotland) Ltd

01-Mar-2007 - ITI Life Sciences announced the signing of two Commercialisation Licence agreements based on intellectual assets created during ITI Life Sciences' Fluorescence Lifetime Assay Programme, using fluorescence lifetime for 3-D cell-based assays and other applications. The first licence, signed with ...

Caliper Life Sciences Launches Comprehensive Drug Discovery and Development Services Business

23-Jan-2007 - Caliper Life Sciences, Inc. unveiled Caliper Discovery Alliances & Services (CDAS), the newly-formed services organization created from the integration of NovaScreen Biosciences, a provider of in vitro discovery services, and Xenogen Biosciences, a provider of in vivo discovery services. ...